Novocure (NVCR) Financials: Revenue & Earnings
NVCR$13.51-0.67 -4.69%
$1.57B
Market Cap
-11.29
P/E
7.11
Forward P/E
—
Score
Novocure (NVCR) Financials: Revenue & Earnings
NVCR price $13.51 -0.67 -4.69%
- Ticker
- NVCR
- Price
- $13.51
- Change
- -0.67 -4.69%
- Market cap ?
- $1.57B
- P/E ?
- -11.29
- Forward P/E ?
- 7.11
- Dividend yield ?
- 0.00%
- Beta ?
- 0.99
- Sector
- Healthcare
- Industry
- Medical - Devices
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 82888000 | 177026000 | 248069000 | 351318000 | 494366000 | 535031000 | 537840000 | 509338000 | 605220000 | 655353000 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain…
Earnings and financials
Novocure Ltd (NVCR) trades at $13.51, with a market cap of $1.57B and a trailing P/E of -11.29. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 82888000 | 177026000 | 248069000 | 351318000 | 494366000 | 535031000 | 537840000 | 509338000 | 605220000 | 655353000 |
Insights · Dividends · Forecast · Financials · Learn